
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
Bioclinica has announced that is has assembled a team of experts dedicated to nonalcoholic fatty liver disease and nonalcoholic steatohepatitis to help sponsors develop therapeutics using medical imaging and other biomarkers in clinical trials.
Read more about it







